An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy
Open Access
- 21 April 2019
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 12 (3), 333-337
- https://doi.org/10.1093/ckj/sfz040
Abstract
Conditions presenting with signs of thrombotic microangiopathies (TMAs) comprise a wide spectrum of different diseases. While pathological hallmarks are thrombosis of arterioles and capillaries, clinical signs are mechanical haemolysis, thrombocytopenia and acute renal injury or neurological manifestations. The current classification of various syndromes of TMA is heterogeneous and often does not take the underlying pathophysiology into consideration. Therefore we propose a simplified classification based on the aetiology of different syndromes leading to TMA. We propose to categorize different TMA syndromes in hereditary and acquired forms and classify them based on the genetic background or underlying conditions. Of course, this classification is not always distinctly applicable in each case and from time to time reassessment of the established diagnosis is strongly recommended. The recommended treatment of TMA in the past was plasma exchange (PE). However, recently, the terminal complement inhibitor eculizumab became commercially available and has shown promising results in different open-label studies and case series. In our centre, first-line therapy is PE; however, patients are instantly switched to complement inhibitory therapy in case of treatment failure or intolerance.Keywords
This publication has 21 references indexed in Scilit:
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2017
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special IssueJournal of Clinical Apheresis, 2016
- Thrombotische MikroangiopathienMedizinische Klinik - Intensivmedizin und Notfallmedizin, 2016
- Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consensoNefrología, 2015
- Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 CasesAmerican Journal of Kidney Diseases, 2014
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Complement disorders and hemolytic uremic syndromeCurrent Opinion in Pediatrics, 2013
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- Complications of apheresis in childrenTransfusion, 2007
- Complications of therapeutic plasma exchange: A prospective study of 1,727 proceduresJournal of Clinical Apheresis, 2007